<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307437</url>
  </required_header>
  <id_info>
    <org_study_id>CR006325</org_study_id>
    <secondary_id>C0743T09</secondary_id>
    <secondary_id>2005-003530-17</secondary_id>
    <nct_id>NCT00307437</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor Research &amp; Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor Research &amp; Development, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of ustekinumab
      (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although numerous therapeutic options exist for the treatment of psoriasis, there is still a
      significant unmet medical need due to the limited effectiveness and/or significant side
      effect profile of current treatment options. Preclinical studies and early phase clinical
      studies suggest that interleukins-12 and -23, two molecules that are part of the
      communication network in the immune system, may play an important role in psoriasis.
      Ustekinumab (CNTO 1275) is a monoclonal antibody directed against interleukins -12 and -23.
      This is a randomized (study drug assigned by chance like flipping a coin), double blind
      (neither physician nor patient knows the name of the assigned drug), parallel-group,
      multicenter study to determine the effectiveness and safety of two different doses of
      ustekinumab (CNTO 1275) administered subcutaneously (under the skin) as compared with placebo
      in patients with moderate to severe plaque-type psoriasis (the most common type of
      psoriasis). The hypothesis is that ustekinumab (CNTO 1275) will be more effective in
      treatment of psoriasis than placebo, that the improvement in psoriasis will result in an
      improved quality of life for treated patients and that ustekinumab (CNTO 1275) will be
      generally well tolerated. Patients will receive ustekinumab (CNTO 1275), 45 or 90 mg, or
      placebo administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter
      until week 52. For patients who partially respond to the starting regimen, the dosing
      interval may be adjusted to every 8 weeks. Patients will enter long term extension portion of
      the study at week 52 during which patients will continue to receive treatment with
      ustekinumab (CNTO 1275) and will be followed for a total of up to 264 weeks from the initial
      (week 0) administration of study agent.

      The dose of ustekinumab (CNTO 1275) will be 45 or 90 mg or placebo administered
      subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter. For patients who
      partially respond to the starting regimen, the dosing interval may be adjusted to every 8
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12</measure>
    <time_frame>Week 0 to Week 12</time_frame>
    <description>Number of participants achieving greater than or equal to 75 percent improvement in PASI at Week 12. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Physician Global Assessment (PGA) of Cleared or Minimal at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of participants achieving a physician global assessment (PGA) (0 [none] to 5 [severe]) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI) at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in Dermatology Life Quality Index (DLQI) from baseline at Week 12. The DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Visits With Psoriasis Area and Severity Index (PASI) 75 From Week 40 Through Week 52</measure>
    <time_frame>Week 40 to Week 52</time_frame>
    <description>Number of visits at which participants randomized at Week 28 achieved at least 75 percent improvement from baseline in PASI from Week 40 through Week 52 in participants randomized at Week 28. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1230</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Group I: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II: Ustekinumab 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III: Ustekinumab 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg</intervention_name>
    <description>Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264</description>
    <arm_group_label>Group I: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab (CNTO 1275) 45 mg</intervention_name>
    <description>Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264</description>
    <arm_group_label>Group II: Ustekinumab 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab (CNTO 1275) 90 mg</intervention_name>
    <description>Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264</description>
    <arm_group_label>Group III: Ustekinumab 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plaque-type psoriasis diagnosed &gt;= 6 months prior

          -  Plaque-type psoriasis covering at least 10% of total body surface areas

          -  Psoriasis area-and-severity index score of &gt;=12 at screening and baseline

          -  Considered by treating dermatologist to be a candidate for phototherapy or systemic
             treatment of psoriasis

          -  Women of childbearing potential and all men must agree to use adequate birth control
             measures throughout the trials and for 12 months following the last injection of study
             agent

          -  Have no history of latent or active tuberculosis (TB)

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis or drug-induced psoriasis

          -  Women who are pregnant or nursing, or men and women planning pregnancy while enrolled
             in the study

          -  Patients who have used any therapeutic agent targeted at reducing IL-12 or IL-23

          -  Patients who have had a Bacillus Calmette-Guerin (BCG) vaccination within the previous
             12 months prior to screening

          -  Patients who have a history of chronic or recurrent infectious disease or who have or
             have had a serious infection requiring hospitalization or intravenous antibiotics
             within the previous 2 months prior to screening

          -  Patients who have or ever have had a nontuberculous mycobacterial infection or
             opportunistic infection

          -  Patients known to be infected with human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C

          -  Patients who have current signs or symptoms of severe, progressive, or uncontrolled
             renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,
             neurologic, cerebral, or psychiatric disease

          -  Patients with a malignancy or who have a history of malignancy (with the exception of
             certain skin cancers and pre-invasive cervical cancer)

          -  Patients participating in another trial using an investigational agent or procedure

          -  Systemic immunosuppressants within 4 weeks of the first administration of study agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich N/A</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton Trials Carried Out</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <results_first_submitted>October 23, 2009</results_first_submitted>
  <results_first_submitted_qc>October 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2012</results_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to Severe Plaque-Type Psoriasis</keyword>
  <keyword>interleukin 23</keyword>
  <keyword>IL-12</keyword>
  <keyword>interleukin-12</keyword>
  <keyword>interleukin-23</keyword>
  <keyword>CNTO1275</keyword>
  <keyword>biologic</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>CNTO 1275</keyword>
  <keyword>IL23</keyword>
  <keyword>interleukin 12</keyword>
  <keyword>IL-23</keyword>
  <keyword>IL12</keyword>
  <keyword>ustekinumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this trial, 1230 participants were randomized to either placebo or ustekinumab (CNTO 1275). There were 70 sites in North America and Europe.</recruitment_details>
      <pre_assignment_details>2 participants from placebo group (in controlled period [CP]) after completing the CP did not crossover to the Placebo -&gt; Ustekinumab 90 mg (after CP) treatment group and they are not included in this group (after CP). Thus, 1199 participants completed the 1st period (CP); however, only 1197 participants started the 2nd period (after CP).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo group</description>
        </group>
        <group group_id="P2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg group</description>
        </group>
        <group group_id="P3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 90 mg group</description>
        </group>
        <group group_id="P4">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg q12wk or q8wk from Week 12 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.</description>
        </group>
        <group group_id="P5">
          <title>Placebo -&gt; Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244.</description>
        </group>
        <group group_id="P6">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 45 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.</description>
        </group>
        <group group_id="P7">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 90 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="409"/>
                <participants group_id="P3" count="411"/>
                <participants group_id="P4" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Control Period.</participants>
                <participants group_id="P5" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Control Period.</participants>
                <participants group_id="P6" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Control Period.</participants>
                <participants group_id="P7" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Control Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="394"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="402"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Control Period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Control Period.</participants>
                <participants group_id="P3" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to after Control Period.</participants>
                <participants group_id="P4" count="197"/>
                <participants group_id="P5" count="195">2 participants from placebo group in CP did not crossover to this group after CP.</participants>
                <participants group_id="P6" count="403"/>
                <participants group_id="P7" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="139"/>
                <participants group_id="P5" count="140"/>
                <participants group_id="P6" count="281"/>
                <participants group_id="P7" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="122"/>
                <participants group_id="P7" count="113"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I: Placebo</title>
          <description>Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
        </group>
        <group group_id="B2">
          <title>Group II: Ustekinumab 45 mg</title>
          <description>Participants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, participants who achieved a greater than and equal to 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.</description>
        </group>
        <group group_id="B3">
          <title>Group III: Ustekinumab 90 mg</title>
          <description>Participants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, participants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="410"/>
            <count group_id="B2" value="409"/>
            <count group_id="B3" value="411"/>
            <count group_id="B4" value="1230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="12.47"/>
                    <measurement group_id="B2" value="45.1" spread="12.06"/>
                    <measurement group_id="B3" value="46.6" spread="12.14"/>
                    <measurement group_id="B4" value="46.2" spread="12.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="274"/>
                    <measurement group_id="B4" value="840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12</title>
        <description>Number of participants achieving greater than or equal to 75 percent improvement in PASI at Week 12. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Week 0 to Week 12</time_frame>
        <population>Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Partcipants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Partcipants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12</title>
          <description>Number of participants achieving greater than or equal to 75 percent improvement in PASI at Week 12. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).</description>
          <population>Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had missing data at Week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="273"/>
                    <measurement group_id="O3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [less than or equal to 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and placebo at an overall significance level of 0.05. Sample Size: With 1200 participants (400 in each treatment group), simulation studies were conducted to calculate the power to detect a treatment difference in the primary endpoint between ustekinumab groups and placebo using a CMH test stratified by baseline weight [&lt;=90kg vs &gt; 90 kg). For all the scenarios evaluated, the power is &gt;99% at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for the multiplicity for the primary endpoint analysis, the Holm’s procedure was used at an overall significance level of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [less than or equal 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Physician Global Assessment (PGA) of Cleared or Minimal at Week 12</title>
        <description>Number of participants achieving a physician global assessment (PGA) (0 [none] to 5 [severe]) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to treat. All participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had missing data at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo partcipants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Partcipants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Partcipants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, partcipants who achieved a greater than and equal to 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physician Global Assessment (PGA) of Cleared or Minimal at Week 12</title>
          <description>Number of participants achieving a physician global assessment (PGA) (0 [none] to 5 [severe]) of cleared or minimal at Week 12. The PGA is 7-point scale used in clinical trials of various diseases. In this the physician checks the state of the disease and gives them score from 0 (clear) to 5 (severe).</description>
          <population>Intent to treat. All participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy or had missing data at Week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="277"/>
                    <measurement group_id="O3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [less than or equal 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and placebo at an overall significancd level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control the multiplicity for the primary and the secondary endpoint analyses, Holm’s procedure was used but the two comparisons for the primary endpoint need to be significant first.</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [less than or equal 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dermatology Life Quality Index (DLQI) at Week 12</title>
        <description>Change in Dermatology Life Quality Index (DLQI) from baseline at Week 12. The DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Participants were included in the analysis according to the assigned treatment groups. Zero change is imputed if the partcipant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo participants received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, participants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 45 mg every 12 week or dose adjust to 45 mg every 8 week dosing.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 28, participants who achieved a greater than and equal 50 percentage but less than 75 percentage improvement in PASI were re-randomized to continue 90 mg every 12 week or dose adjust to 90 mg every 8 week dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dermatology Life Quality Index (DLQI) at Week 12</title>
          <description>Change in Dermatology Life Quality Index (DLQI) from baseline at Week 12. The DLQI is a 10-item questionnaire, that in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Scores range from 0 (no impairment in quality of life) to 30 (most impairment in quality of life).</description>
          <population>Participants were included in the analysis according to the assigned treatment groups. Zero change is imputed if the partcipant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-4.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-14.0" upper_limit="-4.0"/>
                    <measurement group_id="O3" value="-9.0" lower_limit="-14.0" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA on van der Waerden normal scores</method>
            <method_desc>Analysis of variance on van der Waerden normal scores (Conover, 1980) with treatment and baseline weight (≤ 90kg vs &gt; 90 kg) as factors in the model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between ustekinumab 90 mg or 45 mg and placebo at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control the multiplicity for the primary and the secondary endpoint analyses, Holm’s procedure was used but the two comparisons for the primary endpoint and the two comparisons for the 1st second endpoint analyses need to be significant first.</p_value_desc>
            <method>ANOVA on van der Waerden normal scores</method>
            <method_desc>Analysis of varianceon van der Waerden normal scores (Conover, 1980) with treatment and baseline weight (≤90 kg vs &gt;90 kg) as factors in the model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Visits With Psoriasis Area and Severity Index (PASI) 75 From Week 40 Through Week 52</title>
        <description>Number of visits at which participants randomized at Week 28 achieved at least 75 percent improvement from baseline in PASI from Week 40 through Week 52 in participants randomized at Week 28. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).</description>
        <time_frame>Week 40 to Week 52</time_frame>
        <population>All participants randomized at Week 28 were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Ustekinumab 45mg Every 8 Weeks</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4, 16, 28, 36 and 44.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Ustekinumab 45mg Every 12 Weeks</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 4, 16, 28 and 40.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Ustekinumab 90 mg Every 8 Weeks</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4, 16., 28, 36 and 44.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Ustekinumab 90 mg Every 12 Weeks</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Combined (8 Week Dosing)</title>
            <description>Combined Groups 1 and 3 (dosing every 8 weeks)</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Combined (12 Week Dosing)</title>
            <description>Combined Groups 2 and 4 (dosing every 12 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Visits With Psoriasis Area and Severity Index (PASI) 75 From Week 40 Through Week 52</title>
          <description>Number of visits at which participants randomized at Week 28 achieved at least 75 percent improvement from baseline in PASI from Week 40 through Week 52 in participants randomized at Week 28. PASI is a widely used tool for the measurement of severity of psoriasis. This is a test of how bad a person's psoriasis is. The scale combines redness, scaling, and thickness, as well as overall body involvement to determine the PASI score. The scale ranges from 0 (best) to 72 (worst).</description>
          <population>All participants randomized at Week 28 were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy.</population>
          <units>Participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="77"/>
                <count group_id="O6" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="3" lower_limit="1.5" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O5" value="2" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="1" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.468</p_value>
            <method>Cochran-Mantel-Haenszel (row mean score)</method>
            <method_desc>Stratified by baseline weight [less than or equal to 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>Cochran-Mantel-Haenszel (row mean score)</method>
            <method_desc>Stratified by baseline weight [less than or equal to 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between combined q8 group and the combined q12 group, 45 mg q8 and 45 mg q12, 90 mg q8 and 90 mg q12 at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>To control the overall multiplicity, the combined groups was tested first and each dose will then be tested; but the primary and the 1st 2 secondary endpoint analyses need to be significant before this endpoint can be tested.</p_value_desc>
            <method>Cochran-Mantel-Haenszel (row mean score)</method>
            <method_desc>Stratified by baseline weight [less than or equal to 90 kg vs greater than 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 264</time_frame>
      <desc>4 patients in the Ustekinumab 45 mg (after CP) and 7 patients in the Ustekinumab 90 mg (after CP) groups, discontinued study medication during the CP but had follow-up after CP and hence are included in the tables of frequent adverse events and serious adverse events after CP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-12) - Placebo group</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 45 mg group</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-12) - Ustekinumab 90 mg group</description>
        </group>
        <group group_id="E4">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg q12wk or q8wk from Week 12 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.</description>
        </group>
        <group group_id="E5">
          <title>Placebo -&gt; Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving Placebo at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 12 to Week 244.</description>
        </group>
        <group group_id="E6">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 45 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 45 mg q12wk or q8wk from Week 16 to Week 244. Some patients in this group dose escalated from ustekinumab 45 mg to 90 mg after Week 52.</description>
        </group>
        <group group_id="E7">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 12-264) – patients receiving ustekinumab 90 mg at Weeks 0 and 4 -&gt; receiving ustekinumab 90 mg q12wk or q8wk from Week 16 to Week 244.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="73" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cryptogenic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dactylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Glomus tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pityriasis rubra pilaris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="168" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="159" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="342" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="343" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="48" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="137" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="143" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="53" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="112" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="111" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="60" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="45" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="51" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="195"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="407"/>
                <counts group_id="E7" subjects_affected="51" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in &lt;=5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Director, Compound Development Team Leader</name_or_title>
      <organization>Centocor Research &amp; Development, Inc.</organization>
      <phone>1 215 793-7612</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

